Treatment patterns and costs of care for patients with relapsed and refractory Hodgkin lymphoma treated with brentuximab vedotin in the United States: A retrospective cohort study

@inproceedings{Szabo2017TreatmentPA,
  title={Treatment patterns and costs of care for patients with relapsed and refractory Hodgkin lymphoma treated with brentuximab vedotin in the United States: A retrospective cohort study},
  author={Shelagh M Szabo and Ishan Hirji and Karissa M. Johnston and Ariadna Ju{\'a}rez-Garc{\'i}a and Joseph M. Connors},
  booktitle={PloS one},
  year={2017}
}
OBJECTIVES Although brentuximab vedotin (BV) has changed the management of patients with relapsed or refractory Hodgkin lymphoma (RRHL), little information is available on routine clinical practice. We identified treatment patterns and costs of care among RRHL patients in the United States (US) treated with BV. METHODS A retrospective observational study of adults initiating BV for RRHL from 2011-2015, with ≥6 months of data prior to and following BV initiation, was conducted. Treatments were… CONTINUE READING

References

Publications referenced by this paper.
Showing 1-10 of 24 references

Utilization patterns and resource use in relapse / refractory Hodgkin lymphoma ( rrHL ) patients treated with brentuximab vedotin ( BV )

  • C Shao, J Liu, W Zhou, MK Raut, M Monberg, X Cao
  • American Society of Hematology
  • 2016

Similar Papers

Loading similar papers…